Get the Stockscreener App
1.225
12.50%
-0.175
Biovie Inc stock is traded at $1.225, with a volume of 2.34M.
It is down -12.50% in the last 24 hours and down -31.94% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.40
Open:
$1.32
24h Volume:
2.34M
Relative Volume:
1.01
Market Cap:
$9.24M
Revenue:
-
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.2868
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
+11.36%
1M Performance:
-31.94%
6M Performance:
-4.30%
1Y Performance:
-25.76%
1-Day Range:
$1.20
$1.56
1-Week Range:
$1.09
$3.79
52-Week Range:
$0.82
$3.79
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.225 | 10.56M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
515.50 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.71 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.46 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.24 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.25 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - New Castle News
BioVie Phase 2b Parkinson’s Trial Meets Primary Endpoint - Minichart
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
These stocks have an unusual volume in today's session - ChartMill
BioVie Q4 Results: EPS loss narrows 51% YoY to $(0.70) - scanx.trade
BIVI Stock Jumps As SUNRISE-PD Data Fuels Parkinson’s Hopes - timothysykes.com
BIOVIE INC. FY 2026: Net loss $22.1M — 10-K Summary - TradingView
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
BIVI Stock Jumps As SUNRISE-PD Data Fire Up Parkinson’s Hopes - StocksToTrade
BIVI Stock Jumps As SUNRISE-PD Data Ignites Parkinson’s Hopes - timothysykes.com
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why BioVie (BIVI) Stock Is Up Today - Quiver Quantitative
BioVie Inc. Revenue Breakdown – NASDAQ:BIVIW - TradingView
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
New to The Street NASDAQ MARKETSITE - ACCESS Newswire
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results - newswire.com
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
Morgan Stanley (BIVI) discloses 896,822 BioVie shares, an 11.9% stake - Stock Titan
Morgan Stanley (BIVI) discloses 8.0% beneficial stake in BioVie Class A shares - Stock Titan
BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease - Bitget
BioVie Inc (BIVI) Stock News Today - TradingKey
Parkinson's drug developers are betting big on inflammation - Proactive financial news
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results - finance.yahoo.com
BioVie stock sinks on Phase IIb Parkinson’s trial data - Yahoo Finance
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease - markets.businessinsider.com
BioVieBezisterim Shows Statistically Signi - Moomoo
BioVie reports positive phase 2 trial results for Parkinson’s drug By Investing.com - Investing.com South Africa
BioVie shares halve on murky Parkinson’s disease readout - BioSpace
BioVie reports positive phase 2 trial results for Parkinson’s drug - Investing.com
BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program - Fierce Biotech
BIVI Stock Slides As New Equity Offering Looms Over Traders - StocksToTrade
BioVie Announces Positive Phase 2 Parkinson’s Trial Results - TipRanks
Form 8K Biovie Inc For: 6 August By Investing.com - Investing.com Canada
BioVie reports positive Phase 2 SUNRISE-PD topline results for bezisterim showing clinical and biomarker gains - TradingView
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim - Proactive financial news
BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs - Bitget
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial - Yahoo Finance
BioVie Shareholder Notice - TMX Newsfile
BioVie Ongoing Deadline Alert - TMX Newsfile
BioVie Inc. (BIVI) Climbs 6.29% to $1.52 as Momentum Builds Toward $1.60 ResistanceDaily Profile - dars.gov.et
[S-1/A] BIOVIE INC. Amends IPO Registration Statement - Stock Titan
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIVI|BioVie Inc|Price:1.400|Chg%:+0.030 - TradingKey
BIVI|BioVie Inc|Price:1.370| - TradingKey
BioVie Inc (BIVI) Earnings Date & Reports & Earnings News - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):